NCT00008242View on ClinicalTrials.gov

Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

August 31, 2000

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG

dexamethasone

DRUG

doxorubicin hydrochloride

DRUG

thalidomide

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00008242 - Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma | Biotech Hunter | Biotech Hunter